- Home
- IMTX vs RZLT Comparison
IMTX vs RZLT Comparison
Compare IMTX & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- RZLT
- Stock Information
- Founded
- IMTX N/A
- RZLT 2010
- Country
- IMTX Germany
- RZLT United States
- Employees
- IMTX N/A
- RZLT N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- RZLT Health Care
- Exchange
- IMTX Nasdaq
- RZLT Nasdaq
- Market Cap
- IMTX 1.1B
- RZLT 997.7M
- IPO Year
- IMTX N/A
- RZLT N/A
- Fundamental
- Price
- IMTX $10.25
- RZLT $9.89
- Analyst Decision
- IMTX Strong Buy
- RZLT Strong Buy
- Analyst Count
- IMTX 4
- RZLT 6
- Target Price
- IMTX $13.67
- RZLT $15.33
- AVG Volume (30 Days)
- IMTX 654.5K
- RZLT 1.6M
- Earning Date
- IMTX 11-14-2025
- RZLT 11-06-2025
- Dividend Yield
- IMTX N/A
- RZLT N/A
- EPS Growth
- IMTX N/A
- RZLT N/A
- EPS
- IMTX N/A
- RZLT N/A
- Revenue
- IMTX $152,823,253.00
- RZLT N/A
- Revenue This Year
- IMTX N/A
- RZLT N/A
- Revenue Next Year
- IMTX $13.52
- RZLT N/A
- P/E Ratio
- IMTX N/A
- RZLT N/A
- Revenue Growth
- IMTX 83.61
- RZLT N/A
- 52 Week Low
- IMTX $3.30
- RZLT $2.22
- 52 Week High
- IMTX $11.25
- RZLT $11.46
- Technical
- Relative Strength Index (RSI)
- IMTX 56.67
- RZLT 56.21
- Support Level
- IMTX $8.92
- RZLT $8.55
- Resistance Level
- IMTX $10.86
- RZLT $10.62
- Average True Range (ATR)
- IMTX 0.63
- RZLT 0.73
- MACD
- IMTX -0.05
- RZLT 0.01
- Stochastic Oscillator
- IMTX 71.66
- RZLT 45.59
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.